A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration

Part of paid clinical trials in Houston, Texas.

Sponsor
Allergan
Study ID
NCT00395057
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • AGN 211745 — DRUG
    AGN 211745 Solution 1000µg injection at Day 1, Month 1, Month 2
  • AGN 211745 — DRUG
    AGN 211745 Solution 300µg injections, Day 1, Month 1, Month 2
  • AGN 211745 — DRUG
    AGN 211745 Solution 100µg injections, Day 1, Month 1, Month 2
  • Ranibizumab 500µg — DRUG
    Ranibizumab 500µg injections at Day 1, Month 1, Month 2

Study Details

This is a 24-month study to evaluate multiple doses of AGN211745 (previously known as Sirna-027) in treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration

Key Dates

First listed
Nov 2, 2006
Start date
Jan 31, 2007
Status verified
Aug 2015
Primary completion
Oct 31, 2008
Completion
Feb 28, 2009

Study Design

Enrollment
138 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: AGN 211745 Solution 1000 ug
    AGN 211745 Solution 1000 ug
  • Experimental: AGN 211745 Solution 300 ug
    AGN 211745 Solution 300 ug
  • Experimental: AGN 211745 Solution 100 ug
    AGN 211745 Solution 100 ug
  • Active Comparator: Ranibizumab 500 ug
    Ranibizumab 500 ug

Primary Outcome Measure

Percentage of Patients With Improvement in Best Corrected Visual Acuity (BCVA) of 15 or More Letters at Month 3 [ Time Frame: Month 3 ]

Locations (1)

FacilityCityStateZIPSite coordinators
-HoustonTexas--

Find similar trials in Houston, TX

By condition
Age-related macular degeneration
By specialty
OphthalmologyRetina

Related Studies